Navigation Links
Coronary stent leads to complications

It is believed that the rate of clot formation inside a coronary stent is three times higher than the previous procedures. Now a days, the majority of angioplasties involve placement of a stent - a tiny metal device, inside the coronary artery to keep it open. But the very act of placing a stent in the artery irritates the vessel walls and may promote formation of a clot - ironically, the actual problem which the procedure is supposed to prevent.//

Till date, it has been thought that clot formation inside a stent was quite a rare event, affecting one per cent of patients. It is a serious complication, though, which often causes heart attack or sudden death. At the Dutch University Medical Center in the US, a new analysis was carried out by doctors which revealed that the clotting rate was three per cent more. Their investigation covered a larger group of patients who were, on the whole, at risk and required angioplasty.

People with diabetes or who had had a previous heart attack were more likely to suffer a clot in their stent. In order to cut the complication rate, the researchers say that may be people should be given anti-clotting therapy for longer around the time of angioplasty and probably use stent coated with an anti-clotting material in future.


'"/>




Page: 1

Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
2. Coronary heart disease bids Adieu
3. Older Men Surviving Coronary Bypasses
4. The Link Between Oxidized Phospholipids And Coronary Artery Disease
5. Cigarette Smoking Leads To Development Of Type 2 Diabetes In Patients With Coronary Artery Disease
6. New Cardiac Angiography Technique For Improved Imaging Of Coronary Veins
7. Effectiveness Of Drug-Releasing Coronary Stents
8. Children Are At The Risk Of Inheriting Coronary Disease
9. Statin Therapy in Patients with Acute Coronary Syndrome Improves Survival
10. Meditation may Improve Cardiac Risk Factors in Patients with Coronary Heart Disease
11. Microcirculation in Eye May Indicate Coronary Heart Death Risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers Delightful ... Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 ... Delightful Deals on Botox® and Juvederm® just in time for the holiday ...
(Date:12/7/2016)... ... 2016 , ... "ProBrand Flip allows FCPX editors to create unique logo reveals ... of Pixel Film Studios. , ProBrand Flip includes 30 flip book reveal animations. Easily ... from a variety of flip book animations. In Addition, users can modify each preset ...
(Date:12/7/2016)... ... ... Road To Restoration”: an informative and enlightening book for those who believe that ... “The Road To Restoration” is the creation of published author, Thomas Fitzhugh Sheets, seventy-one-year-old ... you could reach out for, and grab, on the old carousels. If you ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma ... by cerebral cavernous angiomas, was awarded a grant from the Julian Grace Foundation ... New Mexico has more people with cavernous angioma than anywhere in the world. ...
(Date:12/7/2016)... ... , ... "Hacking into my medical record wouldn’t be hard for my boyfriend, ... "Margaret in Berlin," Book Twelve in the Margaret of Greenwich ® Young Adult ... novels narrate the lives of a poor teenager and her wealthy friends in the ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... WESTLAKE VILLAGE, Calif. , Dec. 6, ... a privately held, clinical-stage medical dermatology and ... Creabilis plc, a privately held specialty pharmaceutical ... for common inflammatory skin conditions, including psoriasis, ... terms of the agreement, Sienna will make ...
(Date:12/6/2016)... Calif. , Dec. 6, 2016  Regulus ... biopharmaceutical company leading the discovery and development of ... drug development candidates at its R&D day, held ... first candidate, RGLS5040, is an anti-miR targeting microRNA-27 ... second candidate, RGLS4326, is an anti-miR targeting microRNA-17 ...
(Date:12/6/2016)... - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: ... in the use of cannabinoids for the treatment ... 2015 InMed initiated its COPD program using its ... potential active compounds that can be useful for ... assays using human lung fibroblasts (HFL-1 cell line), ...
Breaking Medicine Technology: